{"id":"https://openalex.org/W2019943563","doi":"https://doi.org/10.1158/1538-7445.am10-1574","title":"Abstract 1574: The impact of human wild type EGFR on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies","display_name":"Abstract 1574: The impact of human wild type EGFR on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies","publication_year":2010,"publication_date":"2010-04-01","ids":{"openalex":"https://openalex.org/W2019943563","doi":"https://doi.org/10.1158/1538-7445.am10-1574","mag":"2019943563"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am10-1574","doi":"https://doi.org/10.1158/1538-7445.am10-1574","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am10-1574","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100334557","display_name":"Liang Chen","orcid":"https://orcid.org/0000-0001-7300-6604","observed_orcids":["https://orcid.org/0000-0001-7300-6604"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liang Chen","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003183589","display_name":"Dalia Ercan","orcid":"https://orcid.org/0000-0002-2425-0691","observed_orcids":["https://orcid.org/0000-0002-2425-0691"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dalia Ercan","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017110985","display_name":"Jeonghee Cho","orcid":"https://orcid.org/0000-0003-4422-6266","observed_orcids":["https://orcid.org/0000-0003-4422-6266"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeonghee Cho","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048675362","display_name":"Pasi Antero Janne","orcid":"https://orcid.org/0000-0002-7821-4928","observed_orcids":["https://orcid.org/0000-0002-7821-4928"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pasi A. Janne","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056373767","display_name":"Matthew M. Meyerson","orcid":"https://orcid.org/0000-0002-9133-8108","observed_orcids":["https://orcid.org/0000-0002-9133-8108"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew L. Meyerson","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019034689","display_name":"Kwok\u2010Kin Wong","orcid":"https://orcid.org/0000-0001-6323-235X","observed_orcids":["https://orcid.org/0000-0001-6323-235X","https://orcid.org/0000-0003-1120-8176"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kwok-Kin Wong","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"70","issue":"8_Supplement","first_page":"1574","last_page":"1574"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.009600000455975533,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr-wild-type","display_name":"EGFR wild-type","score":0.9620000123977661},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9279999732971191},{"id":"https://openalex.org/keywords/lung-carcinogenesis","display_name":"lung carcinogenesis","score":0.9470000267028809},{"id":"https://openalex.org/keywords/egfr-overexpression","display_name":"EGFR overexpression","score":0.8859999775886536},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.8429999947547913},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.8059999942779541},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8930000066757202},{"id":"https://openalex.org/keywords/anti-egfr-monoclonal-antibody","display_name":"anti-EGFR monoclonal antibody","score":0.9369999766349792},{"id":"https://openalex.org/keywords/double-transgenic-mice","display_name":"double transgenic mice","score":0.7680000066757202},{"id":"https://openalex.org/keywords/lung-epithelium","display_name":"lung epithelium","score":0.7360000014305115},{"id":"https://openalex.org/keywords/tumor-cell-of-origin","display_name":"tumor cell of origin","score":0.33899998664855957}],"concepts":[{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.858735203742981},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8287031650543213},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6990698575973511},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.6818301677703857},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6780230402946472},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6498382091522217},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.6177711486816406},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.5890809893608093},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5378887057304382},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.4569055140018463},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.4164705276489258},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34606894850730896},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3413914144039154},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.21092021465301514},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.09797483682632446},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am10-1574","doi":"https://doi.org/10.1158/1538-7445.am10-1574","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am10-1574","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8700000047683716}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1968282664","https://openalex.org/W1994763147","https://openalex.org/W2023597833","https://openalex.org/W2120992361","https://openalex.org/W2094962167","https://openalex.org/W2541392164","https://openalex.org/W2076668512","https://openalex.org/W4225893764","https://openalex.org/W2360123363","https://openalex.org/W2168841302"],"abstract_inverted_index":{"Abstract":[0],"Lung":[1],"cancer":[2,9,18,23,126],"is":[3,19,42,48,58,67,97],"the":[4,8,13,20,92,95,124,159,164],"leading":[5],"cause":[6],"of":[7,25,38,55,65,69,94,102,109,123,132,158,163],"related":[10],"death":[11],"in":[12,44,81],"world.":[14],"Non-small":[15],"cell":[16,71],"lung":[17,22,82,88,125,137],"major":[21],"type,":[24],"which":[26],"more":[27],"than":[28],"1.4":[29],"million":[30],"new":[31],"cases":[32],"were":[33],"diagnosed":[34],"each":[35],"year.":[36],"Overexpression":[37],"wild":[39],"type":[40],"EGFR":[41,57,146],"common":[43],"NSCLC.":[45],"However,":[46],"it":[47],"not":[49,53],"clear":[50],"whether":[51],"or":[52],"overexpression":[54,64,108,131],"wt":[56],"tumorigenic.":[59],"We":[60],"recently":[61],"showed":[62],"that":[63,91,120,135],"wt-hEGFR":[66,80,110,133],"capable":[68],"transforming":[70],"lines.":[72],"More":[73],"importantly,":[74],"inducible":[75],"double":[76],"transgenic":[77],"mice":[78],"overexpressing":[79],"epithelial":[83],"compartment":[84],"developed":[85],"poorly":[86],"differentiated":[87],"adenocarcinoma":[89],"and":[90,114,134,145],"maintenance":[93],"tumor":[96,105],"dependent":[98],"on":[99],"continuous":[100],"functioning":[101],"wt-hEGFR.":[103],"The":[104],"driven":[106],"by":[107,130],"responds":[111],"to":[112],"cetuximab":[113],"erlotinib":[115],"treatment.":[116],"These":[117],"data":[118],"suggest":[119],"a":[121],"subpopulation":[122],"may":[127],"be":[128,140],"caused":[129],"these":[136],"cancers":[138],"can":[139],"treated":[141],"with":[142],"anti-EGFR":[143],"antibodies":[144],"tyrosine":[147],"kinase":[148],"inhibitors.":[149],"Citation":[150],"Format:":[151],"{Authors}.":[152],"{Abstract":[153],"title}":[154],"[abstract].":[155],"In:":[156],"Proceedings":[157],"101st":[160],"Annual":[161],"Meeting":[162],"American":[165],"Association":[166],"for":[167],"Cancer":[168,178],"Research;":[169],"2010":[170],"Apr":[171],"17-21;":[172],"Washington,":[173],"DC.":[174],"Philadelphia":[175],"(PA):":[176],"AACR;":[177],"Res":[179],"2010;70(8":[180],"Suppl):Abstract":[181],"nr":[182],"1574.":[183]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}